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Abstract
Background: We investigated the efficacy and prognosis of neoadjuvant chemoradiotherapy (NACRT) for Japanese
locally advanced rectal carcinoma patients.
Methods: Fifty-seven patients diagnosed with cT3-4 or any cT/cN+ disease using enhanced computed tomography
or magnetic resonance imaging from 2002 to 2014 were enrolled. The male/female ratio was 42/15, and the median
age was 67 years. Ra/Rb/Rb-P/P was expressed by 6/35/14/2 patients. Histological tumor types were tub1/tub2/por/
muc in 22/30/4/1 patients. For NACRT, radiotherapy doses were 40–50.4 Gy chemotherapy consisted of 5′-DFUR,
capecitabine, or S1.
Results: All 57 patients received curative surgical treatment. The anal preservation rate was 65.0 %. The ypStage
of 0/I/II/IIIa/IIIb was 7/10/25/11/4 cases. The histological antitumor effect (HATE) was ≥grade (G) 2 and G3 in 31
(54.4 %) and 7 (12.3 %) cases, respectively. Postoperative complications occurred in 17 patients and exceeded GIII
(Clavien–Dindo classification) in four patients. Recurrence was observed in 19 patients; the primary local recurrence rate
was 5.3 %. The 3-year relapse-free survival (RFS) and overall survival (OS) rates were 64.8 and 95.5 %, respectively;
the 5-year RFS and OS rates were 60.2 and 61.0 %, respectively. In multivariate analysis, ypN+ was a high-risk
factor for distant organ recurrence. As predictive factors regarding the efficacy of NACRT, a neutrophil concentration
<70 % and a neutrophil/lymphocyte ratio <3.0 in peripheral blood prior to treatment indicated that NACRT would be
significantly more effective.
Conclusions: NACRT was effective in reducing local recurrence but did not suppress distant organ recurrence in
Japanese locally advanced rectal carcinoma patients. A further investigation of an extension of the NACRT regimen
is required.
Keywords: Neoadjuvant chemoradiotherapy, Rectal cancer
Background
The incidence of colorectal cancer has gradually in-
creased. In Japan, this cancer was ranked as the second
and fourth most common type among women and men,
respectively, in 2014 [1]. Locally advanced rectal cancer
(LARC) has often developed postoperative local recur-
rence. To manage postoperative pelvic local control and
downstage LARC, multimodal therapy such as neoadju-
vant chemoradiotherapy (NACRT) is frequently used in
Western countries [2–4]. Several randomized studies
have shown that NACRT provided better local control
and was more effective than postoperative radiotherapy
[4, 5]. Based on these studies, NACRT for rectal cancer
has been recommended for LARC in the NCCN version
2.2015 guidelines [6].
In Japan, the standard treatment for LARC is total
mesorectal excision and lateral pelvic lymph node dis-
section; postoperative outcomes using surgery alone
were better than those of Western countries, and conse-
quently, NACRT has not been introduced aggressively.
However, in some institutes, adjuvant therapy for LARC
such as chemoradiotherapy (CRT) or chemotherapy has
been introduced. Several phase II studies regarding the
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safety and efficacy of NACRT in Japanese patients have
been reported [7–9].
In the present study, we investigated the usefulness,
efficacy, and prognosis of NACRT in Japanese LARC
patients, concerning the histological antitumor effect
(HATE) and long-term outcomes such as relapse-free
survival (RFS), overall survival (OS), and recurrence rate.
Methods
Between September 2002 and April 2014, a total of 57
patients with LARC underwent NACRT and total mesor-
ectal excision (TME) at the Department of Surgery in
Kansai Medical University Hospital. Inclusion criteria for
this retrospective study were LARC patients with cT3-4
or any cT/cN+ disease assessed using colonoscopy, en-
hanced computed tomography, and magnetic resonance
imaging.
NACRT was administered by a multidisciplinary team
of radiotherapists and colorectal surgeons. The patients
received long-course radiotherapy at two different doses.
At the initial stage of the study, the radiation dose was
40 Gy (4 weeks), and at the latter stage, it was 50.4 Gy
(5.5 weeks). Radiotherapy was performed using the clas-
sic four-field technique. In combination chemotherapy,
three different protocols were used. All patients took
oral fluorouracil, 5′-DFUR, capecitabine, or S1 only on
the day of irradiation.
Surgery was undertaken at 4–6 weeks after NACRT.
We performed abdominoperitoneal resection (APR), low
anterior resection (LAR), internal sphincteric resection
(ISR), and total pelvic floor exenteration (TPE) with
TME; surgery was performed with or without lateral
pelvic lymph node dissection. All patients provided in-
formed consent. The type of surgery was determined at
a preoperative doctor’s conference based on the onco-
logical condition of each patient.
Staging and HATE was performed according to the
Japanese Society for Cancer of the Colon and Rectum
(Eighth Edition) guidelines [10]. The histological tumor
response to NACRT was determined using scale grade
(G) 0, 1a, 1b, 2, and 3 as follows: HATE G0, no response
to treatment; HATE G1a, tumor size reduction of 1/3;
HATE G1b, tumor size reduction of 1/3–2/3; HATE G2,
tumor size reduction of >2/3; and HATE G3, complete
tumor ablation, equal to a pathological complete re-
sponse (pCR).
To investigate the factors associated with postopera-
tive distant organ recurrence, we analyzed age, sex, type
of surgical procedure, histological depth of tumor, HATE
grade, radiation dose, type of combination chemother-
apy, and presence or absence of pathological lymph node
metastasis. To evaluate the predictive factors regarding
the efficacy of NACRT, we analyzed the number of leu-
kocytes, the percentage of neutrophils and lymphocytes,
the neutrophil-to-lymphocyte ratio (NLR), hemoglobin
and albumin levels, platelet count, and carcinoembryonic
antigen (CEA) in peripheral blood prior to treatment.
JMP ver.9 software was used for statistical analysis.
Continuous variables are presented as the median and
range. The univariate analysis data were assessed using
the Yates chi-square test. The Cox regression model (lo-
gistic regression analysis) was used for multivariate ana-
lysis. RFS and OS were analyzed using the log-rank test
and were plotted as Kaplan–Meier curves. In all ana-
lyses, p < 0.05 indicated statistical significance.
Results
Fifty-seven LARC patients who had no distant metasta-
sis and had undergone histopathologically complete re-
section (September 2002 to April 2014) with TME were
enrolled in the study. Patient demographics, preopera-
tive variables, surgical procedure, and postoperative
complications are summarized in Table 1. The study
group consisted of 42 men and 15 women with a median
age of 67 (range, 40–87) years. The location of the
tumor was as follows: 6 patients, Ra; 35 patients, Rb; 14
patients, Rb-P; and 2 patients, P. The median distance
from the lower edge of the tumor to the anal verge was
4.0 cm (0–15 cm). Histological tumor types were as
follows: 22 patients, well-differentiated tubular adeno-
carcinoma; 30 patients, moderately differentiated tubular
adenocarcinoma; 4 patients, poorly differentiated adeno-
carcinoma; and 1 patient, mucinous adenocarcinoma.
There were 17 patients with clinical stage II, 28 patients
with clinical stage IIIa, and 12 patients with clinical stage
IIIb disease. Forty patients (70.2 %) had clinical stage III
disease. Surgical treatments were as follows: 17 patients,
APR (including 5 treated with laparoscopy-assisted sur-
gery (LS)); 10 patients, ISR (including 4 treated with LS);
27 patients, LAR (including 16 treated with LS); and 3
patients, TPE. Although 20 patients underwent bilateral
lateral pelvic lymph node dissection, there were no pa-
tients with lateral pelvic lymph node metastasis. There
were 37 (65.0 %) patients where anal preservation was
achieved. Postoperative complications occurred in 17
(29.8 %) patients, but there were only 4 (7.0 %) pa-
tients with >grade III (Clavien–Dindo classification)
complications.
Details of the NACRT regimen, its therapeutic effects,
and cases of recurrence after surgery are summarized in
Table 2. As part of the NACRT regimen, radiotherapy
was delivered in four fields at a total dose of 40 Gy in 11
patients and 50.4 Gy in 46 patients. Regarding combin-
ation chemotherapy, 31 patients were treated with 5′-
DFUR, 19 with capecitabine, and 7 with S1. A total of 31
(54.4 %) patients had >HATE G2 and 7 (12.3 %) had
HATE G3. Adjuvant chemotherapy was introduced in
31 patients; 12 involved 5′-DFUR, 7 involved tegafur-
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uracil/leucovorin, 5 involved capecitabine, 5 involved
mFOLFOX6, and 2 involved Cape-OX (data not shown).
Recurrence was observed in 19 patients. Recurrence
occurred as follows: 3 patients, local region; 7 patients,
lung; 4 patients, liver; 2 patients, distant lymph nodes; 1
patient, peritoneal dissemination; 1 patient, bone; and 1
patient, gluteus muscle. One of the 7 patients with
HATE G3 had relapse in the liver. The primary local
recurrence rate was 5.3 %.
The results regarding univariate and multivariate ana-
lysis of factors associated with postoperative distant
organ recurrence are detailed in Table 3. Postoperative
distant organ recurrences were more frequent in positive
pathological lymph node metastasis (ypN+) patients
(p = 0.001); the results of multivariate logistic regres-
sion analysis indicated that ypN+ was a significant
predictor of the incidence of distant organ recurrence
(p = 0.009). There was no relationship between the in-
cidence of distant organ recurrence and age, gender,
surgical procedure, histological depth of tumor, HATE
grade, histological type, total radiation dose, and the
type of combination chemotherapy.
The long-term outcomes are shown in Fig. 1. The me-
dian follow-up time regarding RFS and OS was 42
(range 0.5–62.0) months. The 5-year RFS rate was
60.2 % (Fig. 1a), and the 5-year OS rate was 61.0 %
(Fig. 1b). In patients with a HATE grade ≥G2, the 3- and
5-year RFS rates were both 71.4 %. There was no signifi-
cant difference between the RFS rates in the HATE ≥G2
group and the HATE G1 group (3-year RFS rates of 71.4
and 57.7 %, respectively; p = 0.256). The 5-year RFS rates
in ypStages 0, I, II, IIIa, and IIIB were 85.7, 90.0, 67.3,
26.0, and 0 %, respectively; the 5-year OS rate for these
ypStages were 55.6, 100, 69.1, 43.8, and 0 %, respectively.
The 5-year RFS rate in the ypN− group was significantly
higher than that in the ypN+ group (ypN− vs ypN+, 75.4
vs 16.3 %; p < 0.001) (Fig. 2a, b). The 5-year OS rate
in the ypN− group was not significantly different
Table 1 Demographics, preoperative variables, surgical
procedure, and postoperative complications
Gender (male/female) 42/15
Age (year) 67 (range
40–87)
ASA score 1 53
2 4
Tumor location Rb 35
Rb-P 14
Ra 6
P 2
Median distant from lower edge
of tumor to anal verge (cm)
4.0 (0~15)
Histological type tub1 22
tub2 30
por 4
muc 1
Clinical stage II 17
IIIa 28
IIIb 12
Operative procedure
(laparoscopic surgery)
Total perineal excision 3
Abddominoperitoneal
resection
17 (5)
Low anterior resection 27 (16)
Inferior sphincter resection 10 (4)
No. of anus preserving cases (%) 37 (65.0)
No. of patient with complication
(Clavien–Dindo classification
score ≥3)
Overall 17 (4)
Perianal wound infection 2
Bowel obstruction 4 (1)
Stoma related complication 3 (1)
Anastomotic leakage 2 (1)
Abscess in pelvic cavity 2 (1)
Chylous ascites 1
Neurogenic bladder 1
Sepsis (enterocolitis
induced)
1
Radiational enteritis 1
ASA American Society of Anesthesiologists, tub1 well differentiated tubular
adenocarcinoma, tub2 moderately differentiated tubular adenocarcinoma, por
poorly differentiated adenocarcinoma, muc mucinous adenocarcinoma
Table 2 NACRT regimen, effect of NACRT, and recurrence cases
after surgery
NACRT
Radiation dose 40 Gy 11
50.4 Gy 46
Combination chemotherapy 5′-DFUR 31
Capecitabine 19
S1 7
Histological antitumor effect of
NACRT (grade)
1a 8 (14.0 %)
1b 18 (31.6 %)
2 24 (42.1 %)
3 7 (12.3 %)
Recurrence cases Overall 19 (33.3 %)
Local 3
Lung 7
Liver 4
Distant lymph nodes 2
Peritoneum 1
Bone 1
Gluteus maximus 1
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from that in the ypN+ group (ypN− vs ypN+, 72.9 vs
33.8 %; p = 0.111).
The predictive factors of the effect of NACRT (≥G2) are
summarized in Table 4; a rate of neutrophils of <70 %
(p = 0.002) and a NLR score of <3.0 (p = 0.044) in the
peripheral blood prior to treatment indicated that
NACRT would be significantly more effective. There
was no relationship between the efficacy of NACRT and
the leukocyte count, the rate of lymphocytes, the
hemoglobin and albumin levels, the platelet count, or
the CEA score in the peripheral blood.
Discussion
Treatment with NACRT in patients with LARC has been
beneficial in terms of local tumor control and sphincter
preservation [11, 12]. However, the most important goal
of rectal cancer therapy is improvement in survival. In
the present study, the percentage of patients who
Table 3 Univariate and multivariate analysis of factors associated with postoperative distant organ recurrence
Number p value of univariate
analysis
Odd ratio p value of multivariate
analysis
95 % CI
Age ≥ 70 23 0.058 0.525 0.348 0.136–2.090
< 70 34 Reference
Gender Male 42 0.418
Female 15
Surgical procedure APR + TPE 20 0.812
Other operation 37
Histological depth of tumor T0-2 19 0.404
T3, 4 38
Histological antitumor effect G1 26 0.314
G2, 3 31
Histological type por, muc 5 0.096 0.244 0.201 0.024–2.176
tub 52 Reference
Total radiation dose 40 Gy 14 0.524
50.4 Gy 43
Combination chemotherapy 5′DFUR 31 0.442
Capecitabine, S1 26
Pathological lymph nodes metastasis + 15 0.001 0.156 0.009 0.037–0.608
– 42 Reference
Fig. 1 a Kaplan–Meier relapse-free survival (median follow-up time 42 months) of all cases. b Kaplan–Meier overall survival (median follow-up
time 42 months) of all cases. RFS relapse-free survival, OS overall survival
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achieved a HATE grade ≥G2 was 54.4 and 12.3 %
achieved HATE grade G3 (pCR). Although the efficacy
of NACRT regarding local tumor control was proven,
RFS and OS were not significantly prolonged by
NACRT. The 5-year OS rate in patients with ypStage II
disease in our study was 69.1 %. This outcome was simi-
lar to that of Japanese LARC patients with pStage IIIa
disease. Furthermore, the 5-year OS rate (43.8 %) of
patients with ypStage IIIa in our study was similar to
that of Japanese LARC patients with pStage IIIb disease
[10]. This observation demonstrated that NACRT was
effective for the downstaging of LARC but did not con-
tribute to prolongation of the OS of LARC patients.
Similar to our outcome, no survival-prolonging effects
regarding NACRT were demonstrated in previous re-
ports [13, 14].
Schrag et al. reported that >25 % of patients with
LARC had distant organ metastasis [15]. We also found
that 16 patients (28.1 %) exhibited recurrence in distant
organs. Regarding multivariate analysis of the factors as-
sociated with postoperative distant organ recurrence,
ypN+ was found to be a high-risk factor, where the RFS
rate of ypN+ patients was significantly lower than that
of ypN− patients. Fokas et al. reported that a higher ypN
category after preoperative CRT was the strongest prog-
nostic factor regarding multivariate analysis [16]. There
have been some other studies that have reported on other
predictive factors related to recurrence after NACRT.
Toiyama et al. found that C-reactive protein was a promis-
ing predictor of recurrence and prognosis in patients with
rectal cancer after NACRT [17]. Further, factors such as
fibroblast growth factor receptor 2 overexpression [18],
ALDH1 [19], and upregulated polo-like kinase in rectal
cancer [20] were reported to be predictors of recur-
rence after NACRT. Further study will be necessary
to clarify the predictive factors regarding NACRT and
to facilitate improvement of long-term outcomes of
NACRT.
Many predictive biomarkers concerning the antitumor
effect of NACRT have been reported. Patients who
responded well to chemoradiothetapy (CRT) for rectal
cancer had a significantly higher number of pre-CRT
Fig. 2 a Kaplan–Meier relapse-free survival of ypN+ cases and ypN− cases (median follow-up time 42 months). b Kaplan–Meier overall survival of
ypN+ cases and ypN− cases (median follow-up time 42 months). RFS relapse-free survival, OS overall survival
Table 4 Predictive factors in pretreatment peripheral blood
regarding the effectiveness of NACRT (≥grade 2)
Number Chi-square p value of univariate
analysis
Leukocyte count <8000/mm3 0.549 0.459
≥8000/mm3
Rate of neutrophil <70 % 9.189 0.002
≥70 %
Rate of lymphocyte ≥20 % 2.770 0.096
<20 %
NLR score <3.0 4.070 0.044
≥3.0
Hemoglobin level ≥11 g/dl 1.333 0.248
<11 g/dl
Albumin level ≥3.5 g/ml 0.395 0.530
<3.5 g/ml
Platelet count <300,000/μl 0.713 0.398
≥300,000/μl
CEA score <10 ng/ml 0.021 0.886
≥10 ng/ml
Yates chi-square test
NLR neutrophil-to-lymphocyte ratio, CEA carcinoembryonic antigen
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lymphocytes [21]; sustaining a high blood lymphocyte
count during NACRT was predictive of achieving a pCR
in rectal cancer [22]. In addition to this, it has been
reported that predictive biomarkers for NACRT were
tumor differentiation grade and B cell lymphoma 2 ex-
pression [23]. As a negative predictive factor, Flanagan et
al. reported that the increased X-linked inhibitor of
apoptosis protein may be a useful indicator of NACRT
resistance in rectal cancer tissues [24]. In our study,
positive predictive factors regarding the effectiveness of
NACRT (≥G2) were a neutrophil rate <70 % and an
NLR score <3.0, indicating that the therapeutic efficacy
of NACRT may be lower if inflammation is present. As
similar to our data, Krauthamer et al. reported that an
NLR <5 and a serum albumin level >3.5 mg/dL may be
positively related to complete pathological response after
NACRT in patients with clinical stage III LARC [25].
For improving the prognosis of LARC patients, it is ne-
cessary to select other positive biomarkers for predicting
the effectiveness of NACRT by analyzing pretreatment
rectal cancer specimens or blood.
In the present study, we administered oral fluoropyri-
midine anticancer agents, such as 5′-DFUR, capecita-
bine, and S1 with radiotherapy and the pCR rate was
12.3 %. Similar results were obtained using neoadjuvant
single-agent capecitabine plus radiotherapy for LARC
[26]. Recently, cytotoxic agents such as irinotecan and
oxaliplatin plus fluorouracil have been administrated for
combination chemotherapy regarding NACRT [27, 28].
Wong et al. reported that the efficacy of capecitabine
plus irinotecan with radiotherapy and the efficacy of
capecitabine plus oxaliplatin with radiotherapy were
similar in a neoadjuvant setting for LARC patients.
However, it remains uncertain as to whether or not the
addition of a second cytotoxic agent enhances the effect-
iveness of fluorouracil plus radiotherapy [27]. The AC-
CORD 12 trial investigated the value of two different
NACRT regimens involving CAP45 (45 Gy radiotherapy
plus capecitabine) or CAPOX50 (50 Gy radiotherapy
plus capecitabine plus oxaliplatin). Unfortunately, there
were no significant differences in clinical results such as
OS and disease-free survival (DFS) at 3 years, where the
authors did not recommend the administration of oxalipla-
tin with radiotherapy [28]. To evaluate the best combin-
ation chemotherapy with radiotherapy, it will be essential
to plan further large-scale randomized clinical studies.
In our study, adjuvant chemotherapy was introduced
in only 31 (54.4 %) patients. The low introduction rate
of adjuvant chemotherapy possibly resulted in no im-
provement in survival time. There have been several
studies that have reported no benefit of adjuvant chemo-
therapy for LARC after NACRT. Sainato et al. reported
that the addition of adjuvant chemotherapy (5-fluoroura-
cil-folinic acid) in patients with LARC treated with
NACRT did not improve 5-year OS and DFS and had
no impact on the rate of distant metastasis [29]. Rodel et
al. reported that LARC patients after NACRT had a low
compliance to adjuvant chemotherapy [30]. Additionally,
the ACT regimen (adriamycin, cytoxan, and taxol) had no
effect in LARC patients after NACRT [31, 32]. In contrast,
Hong et al. reported that adjuvant FOLFOX (oxaliplatin,
5-fluorouracil, and leucovorin) improved DFS relative to
fluorouracil plus leucovorin in patients with LARC after
NACRT [33], but prolongation of OS was not demon-
strated. It seems likely that improvement in prognosis,
especially prolongation of OS, is difficult after the intro-
duction of ACT after NACRT.
Recently, neoadjuvant chemotherapy (NAC) has been
administered to LARC patients instead of NACRT.
Schrag et al. [15] reported that the outcomes of LARC
patients who underwent FOLFOX chemotherapy with-
out radiotherapy in a neoadjuvant setting were not infer-
ior to those of NACRT. In this study, all patients
exhibited tumor regression, and TME and the pCR rate
after chemotherapy alone were 8 of 32; the 4-year local
recurrence and DFS rates were 0 and 84 %, respectively
[15]. Xiao et al. reported that although there were no
pCR cases, sandwich-like NAC with bevacizumab was
safe and effective for LARC [34]. To confirm the results
of NAC, a randomized trial (PROSPECT trial) has been
initiated in North America [35]. In the near future, NAC
may become the main therapy for LARC after NACRT.
Our study does lack in new insights, however, the
clinical outcomes for Japanese LARC patients after
NACRT have not been established yet. In the future, a
multicenter prospective randomized controlled study in
Japan is necessary to validate the usefulness, efficacy,
and prognosis of NACRT in Japanese LARC patients.
Conclusions
In the present study, NACRT for Japanese LARC pa-
tients was found to be an effective treatment in reducing
local recurrence but did not suppress distant organ re-
currence. NACRT could not prolong RFS and OS. It will
be necessary to change the NACRT regimen and to fur-
ther investigate preoperative multimodal therapy for
LARC such as NAC.
Consent
Written informed consent was obtained from the locally
advanced rectal carcinoma patients for induction of
NACRT.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KT made the substantial contribution to the conception of the study,
conducted a literature search, and drafted the manuscript. KT, KN, and
YU made the contribution for the acquisition of the data. KT, KN, and
Tokuhara et al. World Journal of Surgical Oncology  (2016) 14:136 Page 6 of 7
YU performed the operation. KT, KN, YU, KY, and MK reviewed the
manuscript and gave the final approval for the publication. All authors
read and approved the final manuscript.
Acknowledgements
None.
Received: 10 February 2016 Accepted: 24 April 2016
References
1. National Cancer Center Japan. Projected cancer statistics. Research center for
cancer control and information services, cancer information service. 2014.
Available: http://ganjoho.jp/en/index.html. (Accessed 20 December 2015).
2. Klaassen RA, Nieuwenhuijzen GA, Martijn H, Rutten HJ, Hospers GA, Wiggers
T. Treatment of locally advanced rectal cancer. Surg Oncol. 2004;13:137–47.
3. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al.
Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J
Med. 2006;355:1114–23.
4. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al.
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
N Engl J Med. 2004;351:1731–40.
5. Fleming FJ, Påhlman L, Monson JR. Neoadjuvant therapy in rectal cancer.
Dis Colon Rectum. 2011;54:901–12. doi:10.1007/DCR.0b013e31820eeb37.
6. Benson 3rd AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, et al.
NCCN clinical practice guidelines in oncology, rectal cancer version 2. 2015.
J Natl Compr Canc Netw. 2015;13(6):719–28.
7. Inomata M, Akagi T, Nakajima K, Etoh T, Shiraishi N, Tahara K, et al. Prospective
feasibility study to evaluate neoadjuvant-synchronous S-1 + RT for locally
advanced rectal cancer: a multicenter phase II trial (UMIN ID: 03396).
Jpn J Clin Oncol. 2013;43:321–3. doi:10.1093/jjco/hys219.
8. Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamijo A, Murayama C, et al. Phase
I/II study of preoperative concurrent chemoradiotherapy with S-1 for locally
advanced, resectable rectal adenocarcinoma. Oncology. 2011;81:306–11.
doi:10.1159/000334580.
9. Sato T, Ozawa H, Hatate K, Onosato W, Naito M, Nakamura T, et al. A phase
II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus
irinotecan and radiation in patients with locally advanced rectal cancer:
clinical feasibility and response rate. Int J Radiat Oncol Biol Phys. 2011;79:
677–83. doi:10.1016/j.ijrobp.2009.11.007.
10. Sugihara K, Ajioka Y, Ishiguro S, Isomoto H, Iwashita A, Iwama T, et al. Japanese
classification of colorectal carcinoma, Eighth Edition. Japanese Society for
Cancer of the Colon and Rectum. Tokyo: Kanehara Shuppan; 2013.
11. Berardi R, Maccaroni E, Onofri A, Morgese F, Torniai M, Tiberi M, et al. Locally
advanced rectal cancer: the importance of a multidisciplinary approach. World
J Gastroenterol. 2014;20:17279–87. doi:10.3748/wjg.v20.i46.17279.
12. Marks J, Nassif G, Schoonyoung H, DeNittis A, Zeger E, Mohiuddin M, et al.
Sphincter-sparing surgery for adenocarcinoma of the distal 3 cm of the
true rectum: results after neoadjuvant therapy and minimally invasive
radical surgery or local excision. Surg Endosc. 2013;27:4469–77. doi:10.
1007/s00464-013-3092-3.
13. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al.
Preoperative versus postoperative chemoradiotherapy for locally advanced
rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III
trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.
doi:10.1200/JCO.2011.40.1836.
14. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson
U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on
survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.
15. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al.
Neoadjuvant chemotherapy without routine use of radiation therapy for
patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;
32:513–8. doi:10.1200/JCO.2013.51.7904.
16. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al.
Tumor regression grading after preoperative chemoradiotherapy for locally
advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-
94 trial. J Clin Oncol. 2014;32:1554–62. doi:10.1200/JCO.2013.54.3769.
17. Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, et al.
C-reactive protein as predictor of recurrence in patients with rectal cancer
undergoing chemoradiotherapy followed by surgery. Anticancer Res. 2013;
33:5065–74.
18. Li CF, He HL, Wang JY, Huang HY, Wu TF, Hsing CH, et al. Fibroblast growth
factor receptor 2 overexpression is predictive of poor prognosis in rectal
cancer patients receiving neoadjuvant chemoradiotherapy. J Clin Pathol.
2014;67:1056–61. doi:10.1136/jclinpath-2014-202551.
19. Oh SY, Sohn SH, Yim H, Lee D, Suh KW, Kim YB. ALDH1 is a prognostic factor
for patients treated with neoadjuvant chemoradiotherapy and radical resection
for stage III rectal cancer. J Surg Oncol. 2015;11:243–7. doi:10.1002/jso.23792.
20. Tut TG, Lim SH, Dissanayake IU, Descallar J, Chua W, Ng W, et al.
Upregulated polo-like kinase 1 expression correlates with inferior
survival outcomes in rectal cancer. PLoS One. 2015;10, e0129313.
doi:10.1371/journal.pone.0129313.
21. Tada N, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, et al. Prediction
of the preoperative chemoradiotherapy response for rectal cancer by
peripheral blood lymphocyte subsets. World J Surg Oncol. 2015;13:30.
doi:10.1186/s12957-014-0418-0.
22. Heo J, Chun M, Noh OK, Oh YT, Suh KW, Park JE, et al. Sustaining blood
lymphocyte count during preoperative chemoradiotherapy as a predictive
marker for pathologic complete response in locally advanced rectal cancer.
Cancer Res Treat. 2015. doi:10.4143/crt.2014.351 [Epub ahead of print].
23. García-Flórez LJ, Gómez-Álvarez G, Frunza AM, Barneo-Serra L, Martínez-
Alonso C, Fresno-Forcelledo MF. Predictive markers of response to
neoadjuvant therapy in rectal cancer. J Surg Res. 2015;194:120–6.
doi:10.1016/j.jss.2014.10.005.
24. Flanagan L, Kehoe J, Fay J, Bacon O, Lindner AU, Kay EW, et al. High levels
of X-linked inhibitor-of-apoptosis protein (XIAP) are indicative of radio
chemotherapy resistance in rectal cancer. Radiat Oncol. 2015;10:131.
doi:10.1186/s13014-015-0437-1.
25. Krauthamer M, Rouvinov K, Ariad S, Man S, Walfish S, Pinsk I, et al. A study
of inflammation-based predictors of tumor response to neoadjuvant
chemoradiotherapy for locally advanced rectal cancer. Oncology. 2013;
85:27–32. doi:10.1159/000348385.
26. Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a
radiosensitizing agent in neoadjuvant treatment of locally advanced resectable
rectal cancer: prospective phase II trial. Croat Med J. 2006;47:693–700.
27. Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, et al.
Efficacy endpoints of radiation therapy group protocol 0247: a randomized,
phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine
and irinotecan or capecitabine and oxaliplatin for patients with locally
advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2015;91:116–23.
doi:10.1016/j.ijrobp.2014.09.031.
28. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne
PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial
in rectal cancer. J Clin Oncol. 2012;30:4558–65. doi:10.1200/JCO.2012.42.8771.
29. Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, et al.
No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant
chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term
results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113:223–9.
doi:10.1016/j.radonc.2014.10.006.
30. Rödel C, Trojan J, Bechstein WO, Woeste G. Neoadjuvant short- or long-term
radio(chemo)therapy for rectal cancer: how and who should be treated?
Dig Dis. 2012;30 Suppl 2:102–8. doi:10.1159/000342038.
31. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, et al.
Multidisciplinary rectal cancer management: 2nd European rectal cancer
consensus conference (EURECA-CC2). Radiother Oncol. 2009;92:148–63.
doi:10.1016/j.radonc.2009.06.027.
32. van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L,
et al. EURECCA colorectal: multidisciplinary management: European consensus
conference colon & rectum. Eur J Cancer. 2014;50:1.e1–1.e34. doi:10.1016/j.ejca.
2013.06.048.
33. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Lancet Oncol.
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as
adjuvant chemotherapy for locally advanced rectal cancer after preoperative
chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised
controlled trial. 2014;15:1245-1253. doi: 10.1016/S1470-2045(14)70377-8.
34. Xiao J, Chen Z, Li W, Yang Z, Huang Y, Zheng J, et al. Sandwich-like neoadjuvant
therapy with bevacizumab for locally advanced rectal cancer: a phase II trial.
Cancer Chemother Pharmacol. 2015;76:21–7. doi:10.1007/s00280-015-2763-2.
35. Clinical Trials. Colorectal cancer. Chemotherapy or chemotherapy + radiation for
rectal cancer patients undergoing surgery (the PROSPECT Trial-N1048). 2015.
Available: http://www.seattlecca.org/clinical-trials/coloncancer-NCT01515787.cfm.
(Accessed 20 July 2015).
Tokuhara et al. World Journal of Surgical Oncology  (2016) 14:136 Page 7 of 7
